Synergistic SC@PDA/PVA-R7050 hydrogel system sustains therapeutic release and improves osteoarthritis treatment efficacy.

Osteoarthritis (OA) is the most common degenerative joint disorder, causing chronic pain, stiffness, and progressive loss of articular cartilage. Current treatments primarily manage symptoms, failing to halt disease progression or address underlying inflammation and oxidative stress. There's a critical need for therapies that can mitigate these root causes and promote tissue regeneration, offering a more comprehensive solution than existing standards of care.

Researchers developed SC@PDA/PVA-R7050 Gel, a multi-component drug delivery system for OA. It uses a polyvinyl alcohol (PVA) hydrogel carrier, with polydopamine (PDA) particles to reduce oxidative stress. The TNF-α inhibitor R-7050 was encapsulated, and bone marrow mesenchymal stem cells (MSCs) were incorporated for their regenerative and anti-inflammatory effects. This synergistic design aimed to mitigate inflammation and promote cartilage regeneration. The abstract does not detail specific experimental models or doses.